Bleeding due to acquired dysfibrinogenemia as the initial presentation of multiple myeloma.
BMJ Case Rep
; 12(7)2019 Jul 17.
Article
en En
| MEDLINE
| ID: mdl-31320370
ABSTRACT
Patients with multiple myeloma (MM) are at risk for acquired dysfibrinogenemia resulting in laboratory abnormalities and/or bleeding complications. We describe a 63-year-old man who presented with bleeding diathesis in the presence of a low fibrinogen activity level with a normal fibrinogen antigen level. Further studies revealed elevated levels of lambda free light chains, and he was diagnosed with MM. Despite initiating treatment with bortezomib/dexamethasone, he continued to have recurrent bleeds along with hypofibrinogenaemia, prompting a switch to carfilzomib/dexamethasone. The patient responded with improvement in bleeding symptoms, normalisation of fibrinogen activity and a decrease in serum free light chains.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Afibrinogenemia
/
Hemorragia
/
Mieloma Múltiple
Tipo de estudio:
Etiology_studies
Límite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
BMJ Case Rep
Año:
2019
Tipo del documento:
Article
País de afiliación:
Estados Unidos